News

In a French observational single-centre study 28 virologically suppressed HIV positive patients were enrolled in a study of dolutegravir monotherapy. The median duration of antiretroviral therapy was 17 years and the median CD4 count was 624. Baseline therapy...

149 HIV positive patients from the SCOPE cohort were followed for a median of 8.3 years and evaluated for atherosclerosis and cardiovascular risk factors. Atherosclerosis was evaluated by measuring carotid intima-media thickness (CIMT) with ultrasound in different...

In ACTG5303 treatment naive HIV-positive patients with CCR-5 tropic virus were randomized to either maraviroc or tenofovir (TDF), each in combination with ritonavir-boosted darunavir and emtricitabine (n=262). The study was double blind and placebo controlled. After...

Four HIV positive MSM were treated for AHC (genotype 1) with a combination of sofosbuvir and ledipasvir. Two of the patients also received ribavirin. All four had suppressed HIV viral load. Three received 12 weeks of therapy and one 8 weeks. Two patients showed...

The PIVOT trial was a randomised trial in which monotherapy with a boosted PI was compared to conventional triple therapy in 587 virologically suppressed HIV-positive adults on triple therapy. All boosted PI:s were allowed. Darunavir was the most widely used boosted...

In a multicenter prospective and observational study two different doses of sofosbuvir were given to patients with hepatitis C on hemodialysis. In addition treatment was given with simeprevir, daclatasvir, ledipasvir or ribavirin. Sofosbuvir was given as a daily...

In the FRESH study (Female Rising Through Educational Support and Health) 432 HIV uninfected South African women aged 18-23 were recruited. The study objective was to characterize immune determinants of HIV acquisition including contraceptive use. Participants were...

In the Canadian Coinfection Cohort study (CTN 222) patients with HIV/HCV coinfection were prospectively followed from 2003 to 2014. 1072 patients without baseline significant liver fibrosis or end stage liver disease were included in the study. The association...

In the ION-4 trial HIV/HCV coinfected patients with genotypes 1 and 4 were treated with ledipasvir/sofosbuvir for 12 weeks. SVR12 (sustained viral response) was achieved in 96 %. 9 patients who failed in the original study were given prolonged retreatment....

Thirty HIV-positive volunteers participated in a study where the influence of EFV and boosted Atazanavir (ATV/r) on Atovaquone concentrations was investigated. Ten of the patients took no antiretroviral therapy (cART), ten each took either EFV or ATV/r containing...

Pages